[Asia Economy Reporter Lee Chun-hee] Apclon announced on the 26th that it will expand the clinical phase 1 trial sites for its chimeric antigen receptor (CAR)-T therapy candidate 'AT101' from Seoul to other regions nationwide.
Apclon began clinical administration of AT101 to hematologic cancer patients at Seoul Asan Medical Center in May. Recently, it confirmed three additional clinical hospitals: Ajou University Hospital in Suwon, Gyeonggi Province; Ulsan University Hospital in Dong-gu, Ulsan; and Dong-A University Hospital in Seo-gu, Busan.
Through the phase 1 trial, Apclon plans to determine the maximum tolerated dose of AT101 and the recommended dose for the phase 2 clinical trial.
As CAR-T therapies are advanced biopharmaceuticals, clinical trials require not only specialized medical staff and treatment systems but also dedicated facilities. Currently, CAR-T clinical treatment facilities are concentrated in Seoul.
An Apclon representative stated, “With the expansion of clinical trial sites, we hope that hematologic cancer patients nationwide can receive cutting-edge medical services not only in Seoul but also at regional hospitals. We are focusing on accelerating the clinical trial pace by closely cooperating with each clinical institution and securing the supply chain for samples and CAR-T therapies.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
